Trial Profile
A Phase I Study of 131-1 mIBG Followed by Nivolumab and Dinutuximab Beta in Children With Relapsed/Refractory Neuroblastoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Dinutuximab beta (Primary) ; Iobenguane (Primary) ; Nivolumab (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms Inbraced; MiNivAN
- 26 Oct 2022 Planned End Date changed from 1 Jun 2022 to 1 Nov 2023.
- 26 Oct 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Nov 2023.
- 04 Oct 2021 Planned End Date changed from 1 May 2021 to 1 Jun 2022.